8-K: PDS Biotech: Promising Phase 2 Data for PDS0101 Published

PDS Biotechnology Corporation announced the publication of positive Phase 2 trial results for its immunotherapy PDS0101 in combination with pembrolizumab for HPV16-positive head and neck cancer in JAMA Oncology.

Summary

• PDS Biotechnology Corporation has announced the publication of results from its Phase 2 VERSATILE-002 trial evaluating PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
• The trial data, published in JAMA Oncology, showed a median overall survival (mOS) of 39.3 months in the overall CPS ≥ 1 population, significantly higher than the published 17.9 months for standard of care.
• The objective response rate (ORR) for CPS ≥ 1 was 36% by investigator review and 34% by central review, compared to 19% for standard of care pembrolizumab.
• The treatment combination was well-tolerated, with a 13.8% rate of Grade 3 treatment-related adverse events (TRAEs) and no Grade 5 TRAEs, which is comparable to the 17% Grade 3 TRAEs reported for standard of care pembrolizumab.
• The company is prioritizing PDS0301 for metastatic colorectal cancer and is pursuing a partnership strategy for PDS0101.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the publication of promising Phase 2 trial results in a reputable journal, indicating potential efficacy and a favorable safety profile for PDS0101. However, the score is tempered by the need for further trials and the company's ongoing reliance on financing.

Positives

• Publication of Phase 2 trial results in JAMA Oncology, a peer-reviewed journal, lends significant credibility to the findings.
• Median overall survival (mOS) of 39.3 months in the CPS ≥ 1 population for the PDS0101 combination therapy, which is more than double the published standard of care (17.9 months).
• Objective response rate (ORR) of 36% (investigator) and 34% (central) in the CPS ≥ 1 population, exceeding the published standard of care ORR of 19%.
• Favorable safety profile with a low rate of Grade 3 TRAEs (13.8%) and no Grade 5 TRAEs, comparable to or better than standard of care.
• The results are consistent with promising survival outcomes reported in other studies, including IMMUNOCERV and an NCI-led study.

Negatives

• The trial was open-label and non-randomized, which may introduce bias.
• The mITT population for efficacy analyses included 75 patients, with specific breakdowns for ICI-nave (53 patients) and ICI-resistant (22 patients).
• The company is continuing to prioritize PDS0301, potentially indicating a shift in focus away from PDS0101's immediate development.
• The company intends to pursue strategic partnerships or other externally funded opportunities for Phase 3 development of PDS0101, suggesting a need for external capital and collaboration.

Risks

• The company's ability to continue as a going concern is dependent on future financing.
• Reliance on additional financing to fund operations and complete development and commercialization, with risks that such financing may restrict operations or require relinquishing rights.
• The timing and success of future clinical trials for PDS0301 and other product candidates are uncertain.
• Interpretation of preclinical and early clinical results may not be indicative of final trial outcomes.
• Potential for legislative, regulatory, political, and economic developments outside the company's control.

Future Outlook

The company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101. PDS0301 is being prioritized for development in metastatic colorectal cancer.

Management Comments

• "Were very pleased with the publication of the Phase 2 clinical results of the VERSATILE-002 clinical trial in a leading peer reviewed oncology journal."
• "These results support the durable clinical effect of PDS0101, consistent with promising survival outcomes reported in two other recently published studies, the IMMUNOCERV study, and the NCI-led study in HPV16-positive recurrent and/or metastatic cancers."
• "We believe PDS0101 has the potential to bring new hope to the rapidly growing population of HPV16-positive head and neck cancer patients."

Industry Context

StockSavvy.ai notes that the publication of these Phase 2 results in JAMA Oncology is a significant milestone for PDS Biotech, positioning PDS0101 as a potentially valuable combination therapy in the competitive immuno-oncology landscape for HPV-driven cancers. The comparison to standard of care benchmarks highlights the potential differentiation of their approach.

Comparison to Industry Standards

• The median overall survival (mOS) of 39.3 months for the PDS0101 combination in CPS ≥ 1 patients is notably higher than the published standard of care (pembrolizumab or pembrolizumab + chemotherapy) of 17.9 months.
• The objective response rate (ORR) of 36% (investigator) / 34% (central) for CPS ≥ 1 patients surpasses the published ORR of 19% for standard of care pembrolizumab.
• The Grade 3 treatment-related adverse event rate of 13.8% is comparable to or better than the 17% reported for standard of care pembrolizumab.

Stakeholder Impact

• Shareholders may see increased interest due to positive clinical trial results, but future development depends on financing and partnerships.
• Patients with HPV16-positive head and neck cancer may benefit from a new, potentially more effective treatment option.
• Healthcare providers will have new data to consider for treatment protocols in recurrent/metastatic head and neck cancer.

Next Steps

• Pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101.
• Continue to prioritize PDS0301 in metastatic colorectal cancer.

Key Dates

Recommendation

The publication of strong Phase 2 data for PDS0101 is a significant positive catalyst. However, the company's reliance on external financing for future development and the need to secure partnerships for Phase 3 trials introduce considerable execution risk. While the results are promising, the path to commercialization remains uncertain, warranting a 'hold' recommendation until further clarity on financing and partnership agreements emerges.

Keywords

PDS0101, Head and Neck Cancer, Immunotherapy, JAMA Oncology, Phase 2 Trial, Pembrolizumab, HPV16, Clinical Trial Results